Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam

PLoS One. 2021 Dec 23;16(12):e0261231. doi: 10.1371/journal.pone.0261231. eCollection 2021.

Abstract

Introduction: Few economic evaluations have assessed the cost-effectiveness of screening type-2 diabetes mellitus (T2DM) in different healthcare settings. This study aims to evaluate the value for money of various T2DM screening strategies in Vietnam.

Methods: A decision analytical model was constructed to compare costs and quality-adjusted life years (QALYs) of T2DM screening in different health care settings, including (1) screening at commune health station (CHS) and (2) screening at district health center (DHC), with no screening as the current practice. We further explored the costs and QALYs of different initial screening ages and different screening intervals. Cost and utility data were obtained by primary data collection in Vietnam. Incremental cost-effectiveness ratios were calculated from societal and payer perspectives, while uncertainty analysis was performed to explore parameter uncertainties.

Results: Annual T2DM screening at either CHS or DHC was cost-effective in Vietnam, from both societal and payer perspectives. Annual screening at CHS was found as the best screening strategy in terms of value for money. From a societal perspective, annual screening at CHS from initial age of 40 years was associated with 0.40 QALYs gained while saving US$ 186.21. Meanwhile, one-off screening was not cost-effective when screening for people younger than 35 years old at both CHS and DHC.

Conclusions: T2DM screening should be included in the Vietnamese health benefits package, and annual screening at either CHS or DHC is recommended.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Community Health Centers / economics
  • Cost-Benefit Analysis
  • Delivery of Health Care
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / economics
  • Diagnostic Screening Programs / economics*
  • Hospitals, District / economics
  • Humans
  • Hypoglycemic Agents / economics
  • Mass Screening / economics
  • Quality-Adjusted Life Years
  • Vietnam / epidemiology

Substances

  • Hypoglycemic Agents

Grants and funding

This study was supported by Mahidol University and the International Decision Support Initiative (iDSI) through a grant awarded to UC (OPP1087363). This work was produced as part of the International Decision Support Initiative (www.idsihealth.org), which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. The findings, interpretations and conclusions expressed in this article do not necessarily reflect the views of the aforementioned funding agencies.